WO2023002944A1 - 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体 - Google Patents

新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体 Download PDF

Info

Publication number
WO2023002944A1
WO2023002944A1 PCT/JP2022/027860 JP2022027860W WO2023002944A1 WO 2023002944 A1 WO2023002944 A1 WO 2023002944A1 JP 2022027860 W JP2022027860 W JP 2022027860W WO 2023002944 A1 WO2023002944 A1 WO 2023002944A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
sars
cov
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/027860
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
慎哉 渡辺
順一 今井
葉月 志賀
慈子 佐藤
進 松倉
裕孝 星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fukushima Cell Factory Inc
Medicrome Inc
Fukushima Medical University PUC
Original Assignee
Fukushima Cell Factory Inc
Medicrome Inc
Fukushima Medical University PUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fukushima Cell Factory Inc, Medicrome Inc, Fukushima Medical University PUC filed Critical Fukushima Cell Factory Inc
Priority to JP2023536736A priority Critical patent/JPWO2023002944A1/ja
Publication of WO2023002944A1 publication Critical patent/WO2023002944A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A41—WEARING APPAREL
    • A41D—OUTERWEAR; PROTECTIVE GARMENTS; ACCESSORIES
    • A41D13/00—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches
    • A41D13/05—Professional, industrial or sporting protective garments, e.g. surgeons' gowns or garments protecting against blows or punches protecting only a particular body part
    • A41D13/11—Protective face masks, e.g. for surgical use, or for use in foul atmospheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A62—LIFE-SAVING; FIRE-FIGHTING
    • A62B—DEVICES, APPARATUS OR METHODS FOR LIFE-SAVING
    • A62B18/00—Breathing masks or helmets, e.g. affording protection against chemical agents or for use at high altitudes or incorporating a pump or compressor for reducing the inhalation effort
    • A62B18/02—Masks
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material

Definitions

  • the antibody or antibody fragment thereof of the present invention is [2] The antibody or antibody fragment thereof according to [1] above,
  • the receptor binding domain (RBD) of the S1 subunit is characterized by being a polypeptide consisting of the amino acid sequence of SEQ ID NO: 7 or a polypeptide having mutations in said polypeptide.
  • the antibody or antibody fragment thereof of the present invention is [5] Specific to at least one strain selected from the group consisting of SARS-CoV-2 Wuhan strain, Alpha strain, Beta strain, Gamma strain, Delta strain, Epsilon strain, Theta strain, Kappa strain, and Omicron strain
  • SARS-CoV-2 specifically binds to all of Wuhan, Alpha, Beta, Gamma, Delta, Epsilon, Theta, Kappa, and Omicron strains of SARS-CoV-2 [1] It is characterized by being the antibody or antibody fragment thereof according to any one of [4].
  • the antibody or antibody fragment thereof of the present invention is [7] The antibody or antibody fragment of [4] above, which is a multimerized human IgA antibody.
  • the antibody according to the present invention is an antibody that strongly binds to the S1 region of SARS-CoV or SARS-CoV-2, and can be used for SARS-CoV or SARS-CoV-2 infection prevention (prevention). Furthermore, the antibody of the present invention can be applied to antibody-containing sprays, antibody-containing masks, and the like, in addition to pharmaceuticals.
  • the antibody or antibody fragment thereof according to the present invention is selected from the group consisting of Wuhan strain, Alpha strain, Beta strain, Gamma strain, Delta strain, Epsilon strain, Theta strain, Kappa strain, and Omicron strain. It specifically binds to the receptor binding domain (RBD) of the S1 subunit of the spike protein extracellular domain from at least one selected strain.
  • RBD receptor binding domain
  • at least one strain selected from the group consisting of Wuhan strain, Alpha strain, Beta strain, Gamma strain, Delta strain, Epsilon strain, Theta strain, Kappa strain, and Omicron strain, 1 to 9 from the group All combinations of strain selections are included.
  • the heavy chain CDR1 in the antibody or antibody fragment thereof of the present invention consists of the amino acid sequence of SEQ ID NO: 1; heavy chain CDR2 consists of the amino acid sequence of SEQ ID NO: 2; Consists of arrays.
  • the light chain CDR1 in the antibody or antibody fragment thereof of the present invention consists of the amino acid sequence of SEQ ID NO:4; the light chain CDR2 consists of the amino acid sequence of SEQ ID NO:5; and the light chain CDR3 consists of the amino acid sequence of SEQ ID NO:6. .
  • One embodiment of the antibody or antibody fragment thereof according to the present invention comprises a heavy chain variable region consisting of any amino acid sequence selected from the group consisting of (a) to (c) below: (a) the amino acid sequence of SEQ ID NO:8; (b) an amino acid sequence having at least 90% identity with the sequence of the framework region other than each CDR sequence in the sequence of (a) above, and (c) an amino acid sequence in which one or several amino acids are deleted, substituted or added in the sequence of the framework region other than each CDR sequence in the sequence of (a) above (b) or (c) above
  • the heavy chain variable region consisting of the specified amino acid sequence is the SARS-CoV or SARS-CoV-2 S1 subunit receptor binding domain (RBD ).
  • the method for supporting a composition containing an antibody or antibody fragment thereof on a substrate is not limited as long as the antibody can be supported on the substrate.
  • a method of impregnating the material with an antibody-containing solution (liquid composition) having an appropriate concentration and drying at an appropriate temperature and time can be mentioned.
  • a method of impregnating a base material with an antibody-containing solution to support an antibody can be performed with reference to, for example, JP-A-2010-131537.
  • the antibody may be supported on the substrate via a linker.
  • composition for food and drink containing the above antibody or antibody fragment thereof. Since the food and drink composition of the present invention contains an antibody or antibody fragment thereof that has an affinity for SARS-CoV or SARS-CoV-2, SARS-CoV or SARS-CoV-2 taken into the body is , inhibits entry into cells in the intestine, etc. Therefore, in one embodiment, the composition for food and drink of the present invention can be provided as a composition for food for preventing infection with SARS-CoV or SARS-CoV-2.
  • the form of the composition for food and drink may be liquid, paste, gel-like solid, powder, or the like.
  • Another aspect of the present invention provides a method for producing an antibody, comprising the steps of culturing the host cell of the present invention and collecting the target antibody from the culture obtained in the step.
  • the antibody production method may include the step of preparing a cell culture medium, and may include the step of purifying the anti-SARS-CoV antibody or the anti-SARS-CoV-2 antibody. .
  • Alexa Fluor 488 Labeling of Anti-His-tag Antibody An anti-His-tag antibody (abcam, Cat. ab9108) was labeled according to the procedure of the Alexa Fluor 488 Antibody Labeling Kit (ThermoFisher Scientific, A20181).
  • the gene (SEQ ID NO: 28) encoding JCHAIN (Joining Chain Of Multimeric IgA And IgM) for co-expression with the IgA antibody gene was subcloned into the vector pcDNA3.2/V5-DEST (Invitrogen (ThermoFisher SCIENTIFIC)). bottom.
  • Example 2. Antibody evaluation 1 by protein microarray 2-1. Antibody production The antibody gene obtained in "1-9. Determining the antibody gene sequence" and the gene encoding JCHAIN were introduced into expi293 mammalian cells using the ExpiFectamine 293 Transfection Kit (Gibco (ThermoFisher SCIENTIFIC), A14524). , was transiently expressed and antibodies were generated. Specifically, shaking culture of cryopreserved human floating cells was started in a 125 ml flask. A minimum of two passages were performed to allow cells to recover from freeze-thaw injury.
  • the preceding antibodies (REGN10987, AZD1061, LY_CoV16, AZD8895, REGN10933, S309), IgA isotype control antibody (Invitrogen; Cat # 31148, Lot # WF3292542), Nanobody antibody (Absolute Antibody; Cat # Ab02013-1.159 , Lot # Sb #15), WHO standard pooled convalescent plasma from SARS-CoV-2 patients (dilution from neat) was used. Intermediate activity evaluation by this study was outsourced to Charles River Discovery Research Services UK Ltd. All tests were performed in triplicate for each condition.
  • the expression plasmid vector used has a hygromycin-resistant gene
  • cells were cultured in a medium containing 50 ⁇ g/ml hygromycin B (Thermo Fisher Scientific, cat#10687010) to select cells introduced with each protein expression plasmid vector.
  • the obtained cells were designated as SSC#000364 (human ACE2 stably expressing cells).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Birds (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Pulmonology (AREA)
PCT/JP2022/027860 2021-07-19 2022-07-15 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体 Ceased WO2023002944A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023536736A JPWO2023002944A1 (https=) 2021-07-19 2022-07-15

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021118822 2021-07-19
JP2021-118822 2021-07-19
JP2022-011847 2022-01-28
JP2022011847 2022-01-28

Publications (1)

Publication Number Publication Date
WO2023002944A1 true WO2023002944A1 (ja) 2023-01-26

Family

ID=84979266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/027860 Ceased WO2023002944A1 (ja) 2021-07-19 2022-07-15 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体

Country Status (2)

Country Link
JP (1) JPWO2023002944A1 (https=)
WO (1) WO2023002944A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331085A (zh) * 2024-10-16 2025-01-21 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592594A (zh) * 2020-03-13 2020-08-28 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
KR102229225B1 (ko) * 2020-09-04 2021-03-19 (주)셀트리온 사스-코로나바이러스-2 표면의 스파이크 단백질에 결합하는 사스-코로나바이러스 감염증의 진단용 결합 분자

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111592594A (zh) * 2020-03-13 2020-08-28 北京大学 一种抗新型冠状病毒的单克隆抗体及其应用
KR102205028B1 (ko) * 2020-03-22 2021-01-20 (주)셀트리온 사스-코로나바이러스-2에 중화 활성을 갖는 결합 분자
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
KR102229225B1 (ko) * 2020-09-04 2021-03-19 (주)셀트리온 사스-코로나바이러스-2 표면의 스파이크 단백질에 결합하는 사스-코로나바이러스 감염증의 진단용 결합 분자

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119331085A (zh) * 2024-10-16 2025-01-21 中国科学院合肥物质科学研究院 沙贝冠状病毒广谱中和抗体及其应用

Also Published As

Publication number Publication date
JPWO2023002944A1 (https=) 2023-01-26

Similar Documents

Publication Publication Date Title
CN115066435B (zh) 针对lilrb2的单域抗体
TWI356062B (en) Therapeutic peptides and method
KR101785290B1 (ko) 중증 열성 혈소판 감소 증후군 바이러스 감염 진단용 단클론항체, 이를 생산하는 하이브리도마 및 이 단클론항체를 사용하는 중증 열성 혈소판 감소 증후군 바이러스 감염 진단방법
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
KR102122618B1 (ko) 인플루엔자 중화를 위한 작용제
CN110526971A (zh) 抗-CD38抗体和与致弱干扰素α-2B的融合体
CN103665155B (zh) 一种抗流感病毒广谱中和性的中和分子1f2
KR20240006575A (ko) SARS-CoV-2에 대한 사람 중화 모노클로날 항체 및 이의 용도
CN108752460A (zh) 一种高亲和力的pd-1膜外区突变体的融合蛋白及其药物组合物和用途
WO2023002944A1 (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）およびＳＡＲＳコロナウイルス（ＳＡＲＳ－ＣｏＶ）に結合する抗体
Wang et al. Development and identification of porcine monoclonal antibodies against PEDV from single B cells
WO2023190851A1 (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
JP2023152613A (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
WO2023190852A1 (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
CN101798351B (zh) 人TIM-1-Fc融合蛋白的重组表达
JP2023061249A (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
JP2023061248A (ja) 新型コロナウイルス（ＳＡＲＳ－ＣｏＶ－２）に結合する抗体
JP5683466B2 (ja) 抗ｐｓｋ抗体
CN103665156B (zh) 一种抗流感病毒广谱中和性的结合分子3e1
US20240228592A1 (en) Antibody and fusion protein for treating coronaviruses and use thereof
US20170313764A1 (en) Hepatitis c virus specific antibody
US10888615B2 (en) Neutralizing human monoclonal antibody 8D6 against HCV infection
CN103665157B (zh) 一种抗流感病毒广谱中和性的中和分子1c4
WO2023083377A1 (en) Humanized monoclonal antibody for restoring dysfunctional human t and b cells against cancer and viral infection
WO2025024431A1 (en) Broadly reactive antibodies to influenza b viruses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22845878

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023536736

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22845878

Country of ref document: EP

Kind code of ref document: A1